National Bleeding Disorders Foundation/X
Aug 31, 2025, 09:45
Slow Uptake of Hemophilia Gene Therapies: Challenges in Access and Adoption
National Bleeding Disorders Foundation (NBDF) shared on X:
”A new forum piece in Research and Practice in Thrombosis and Haemostasis explores the complex factors at play, from long-term efficacy and safety questions to cost, access, and patient decision-making.
Read the full open-access article.”
A recent RPTH forum article examines why the uptake of hemophilia gene therapy remains modest, citing concerns over long-term efficacy and safety, high costs, access barriers, and competition from effective non-factor therapies.
Latest news in the field of bleeding disorders featured in Hemostasis Today.
-
Sep 24, 2026, 18:43Hugh Nguyen: Honored to Accept the Friend of Singapore Red Cross Award
-
Sep 24, 2026, 18:42Titilope Fasipe: Proud to Support American Society of Hematology’s SCD Initiative
-
Sep 24, 2026, 18:34Ifeanyichukwu Ifechidere: Why Coagulation Samples Can Be “Too Valuable to Throw Away”?
-
Sep 24, 2026, 18:33Aswin K. Mohan: When a Superpower Hears the Call for Blood
-
Sep 24, 2026, 18:31Mercy Lung’aho: Anemia Is Not Only An Iron Problem
-
Sep 24, 2026, 18:29Nick Hanson: Before a Dementia Diagnosis Check Vitamin B12
-
Sep 24, 2026, 18:28Rachel McBryan: Nearly One in Five Older Canadians Has Low Vitamin B12
-
Sep 24, 2026, 18:27Kemal Karaagac: Early DOAC Initiation After Acute Ischaemic Stroke in Atrial Fibrillation
-
Sep 24, 2026, 18:26Mohammed A. AlOmar: What Characterizes Young Stroke in the UAE?